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Abstract The epidermal growth factor receptor (EGFR)
has been implicated in the pathogenesis, therapy and
prognosis of various tumor types. The aim of this study
was to investigate EGFR expression in a large series of
testicular germ cell tumors (TGCTs). A total of 88
TGCTs (37 of pure type and 51 of mixed type)
comprising a total of 44 seminoma, 49 embryonal
carcinoma, 32 yolk sac tumor, 28 teratoma and 7
choriocarcinoma components were immunostained for
EGFR. EGFR reactivity was observed in the stromal cells
of embryonal carcinoma (29%) and in epithelial com-
partments of teratoma (71%). In addition, EGFR staining
was consistently detected in syncytiotrophoblastic cells of
choriocarcinoma, seminoma, embryonal carcinoma and
yolk sac tumor components. EGFR staining, similar to b-
human chorionic gonadotropin (HCG) immunohisto-
chemistry, was efficiently able to identify syncytiotro-
phoblastic cells in TGCTs. This study shows that EGFR is
expressed in a subset of testicular germ cell tumors and
suggests that EGFR may be a useful marker for syncy-
tiotrophoblastic cells.
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Introduction
The epidermal growth factor receptor (EGFR) is a 170-
kDa growth factor receptor tyrosine kinase [20]. Upon
binding of its cognate ligands, which include EGF and
transforming growth factor alpha (TGFa), it activates
signal transduction cascades that contribute to the control
of cell differentiation, proliferation, apoptosis, migration
and adhesion [25]. The EGFR protein is frequently
overexpressed in various types of cancer, and its overex-
pression has been correlated with poor prognosis in head
and neck, ovarian, cervical, bladder and esophageal
cancer [17, 19]. Novel treatment modalities that specif-
ically inhibit EGFR-mediated signal transduction have
recently become available [14]. This development pro-
vides a rationale for the systematic identification of tumor
types that overexpress EGFR and therefore represent
potential candidates for EGFR-targeted therapy.
Testicular germ cell tumors (TGCTs) are the most
common type of cancer in young adult males. TGCTs can
be classified as seminomas and non-seminomatous germ
cell tumors, the latter group comprising embryonal
carcinoma, yolk sac tumor, polyembryona, teratoma and
chroriocarcinoma [6]. TGCTs occur either as tumors with
one homogeneous histological pattern (pure types) or
show more than one histological pattern (mixed types).
The various histological forms of TGCT are clinically and
biologically diverse despite sharing intratubular malig-
nant germ cells as a common precursor [2, 3, 5]. Multi-
agent cisplatin-based chemotherapy has significantly
improved the prognosis of patients with advanced TGCT.
However, disease recurrence and progression still occur,
indicating the need for additional treatment modalities
[2].
The purpose of the present study was to analyze the
expression of the EGFR protein in a large series of TGCT
using immunohistochemistry.
Materials and methods
A total of 182 TGCTs were retrieved from the surgical pathology
files of the Department of Pathology, University of Zrich,
covering a period of 9 years (1993 to 2001). Tumors were
classified according to the World Health Organization (WHO)
classification of testis tumors [16]. Eighty-eight TGCTs were
selected for EGFR immunohistochemistry. This group consisted of
37 pure-type and 51 mixed-type TGCTs comprising a total of 44
seminoma, 49 embryonal carcinoma, 32 yolk sac tumor, 28
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teratoma and 7 choriocarcinoma components (Table 1). Immuno-
staining was performed on one to four representative tissue blocks
for each tumor. Three-micron-thick sections of formalin-fixed,
paraffin-embedded tissue samples were mounted on glass slides
(SuperFrost Plus; Menzel, Braunschweig, Germany), dried for
20 min at 59C, deparaffinized and rehydrated. Prior to incubation
with primary antibody (EGFR, clone 31G7, dilution 1:30; Zymed
Laboratories, San Francisco, USA), antigen retrieval was per-
formed with the Ventana protease 1 reagent (Ventana Medical
Systems, Tucson, Arizona, USA) for 2 min. Pretreatment of
sections, antibody incubation and detection of primary antibody
(Ventana Enhanced Alkaline Phosphatase Red Detection Kit) were
performed on a Benchmark immunohistochemistry staining system
(Ventana Medical Systems). EGFR immunoreactivity was scored
separately for each histological component. Epidermis of normal
human skin was used as a positive control, and primary antibody
was omitted in negative controls.
For b-human chorionic gonadotropin (b-HCG) staining, antigen
retrieval was performed with Ventana cell conditioning solution for
36 min at 100C prior to incubation with primary antibody (b-
HCG, clone h6, dilution 1:20.000; BMA Biomedicals, Augst,
Switzerland). Pretreatment of sections, antibody incubation and
detection of primary antibody (Ventana Basic DAB Detection Kit)
were performed on a Benchmark immunohistochemistry staining
system.
Results
EGFR staining was comparable in pure and mixed-type
TGCTs. A strong membranous EGFR immunoreactivity
was found in syncytiotrophoblastic cells of choriocarci-
nomas (100%; Fig. 1A). EGFR expression was also
detected in the majority of teratomas (71%). Staining was
found in squamous and columnar epithelia with predom-
inant labeling of the basal cell layers (Fig. 1B, C),
whereas cartilage and other non-epithelial (e.g. neural)
tissues remained unstained. In 29% of embryonal carci-
nomas, EGFR immunostaining was observed in the
stromal tumor cell compartment (Fig. 1D). EGFR immu-
noreactivity was absent in seminoma and yolk sac tumor
cells. No EGFR staining was observed in intratubular
malignant germ cells.
To study a potential role for EGFR as a marker for
syncytiotrophoblastic cells, adjacent sections of 38 tumor
samples with syncytiotrophoblasts were stained for EGFR
and b-HCG [9]. In addtion to choriocarcinoma, syncy-
tiotrophoblastic cells were found in 5 seminoma, 20
embryonal carcinoma and 10 yolk sac tumor components.
In all tumors (100%), syncytiotrophoblastic cells identi-
fied by b-HCG immunohistochemistry also showed
strong EGFR staining (Fig. 1E).
Discussion
In this study, we demonstrated EGFR expression in a
subset of TGCTs, namely in the stromal compartment of
embryonal carcinomas and in the squamous and columnar
epithelia of teratomas. EGFR staining in the basal layers
of squamous and columnar epithelia is consistent with the
physiological functions of the EGFR in the proliferation
and differentiation control of epithelial cells [25]. EGFR
expression was also found in syncytiotrophoblastic cells,
either as components of choriocarcinoma or scattered as
single cells in other types of TGCT. This expression
pattern corresponds to previous observations that EGFR is
expressed in the implantation trophoblast, in the tropho-
blast of normal placenta and in gestational trophoblastic
diseases [1, 7, 10, 11, 22].
TGCTs are often associated with elevated serum HCG
levels, which can be due to the presence of either
choriocarcinoma or single syncytiotrophoblasts. Differ-
entiation between these possibilities is clinically impor-
tant. Identification of choriocarcinoma in a mixed TGCT
is associated with poor prognosis, whereas scattered
syncytiotrophoblastic cells appear to exert no adverse
effects on survival [21, 23, 24]. Immunohistochemical
characterization of syncytiotrophoblastic cells has re-
vealed expression of b-HCG [9], pregnancy-specific beta-
1-glycoprotein [12], human placental lactogen [12],
inhibin [13], epithelial membrane antigen [18], and
cytokeratins 7, 8, 18 and 19 [4, 6]. Of these, b-HCG
has been considered to be the most valuable marker for
syncytiotrophoblastic cells. We found that EGFR immu-
nolabelling was able to detect syncytiotrophoblasts with
an efficiency comparable to that of b-HCG staining. This
result suggests that the EGFR can be used as a marker for
syncytiotrophoblastic cells instead of b-HCG or to resolve
an equivocal b-HCG staining.
Two recent studies have also used immunohistochem-
istry to investigate EGFR expression in TGCTs [8, 15].
Our observation of EGFR expression in choriocarcinoma
and single syncytiotrophoblastic cells confirms these
previous results [8, 15]. In addition, we also found EGFR
expression in embryonal carcinomas and teratomas,
which had not been reported previously. These differ-
ences are most likely due to the larger size of our TGCT
series and the more detailed histological analysis in our
study.
Novel treatment modalities that specifically target
EGFR signal transduction, such as anti-EGFR monoclo-
nal antibodies and tyrosine kinase inhibitors, have
Table 1 Epidermal growth fac-
tor receptor (EGFR) expression
in testicular germ cell tumors
according to histological tumor
type
Histological tumor type Number of tumor components EGFR reactivity
Seminoma 44 0a
Embryonal carcinoma 49 14 (29%)a
Yolk sac tumor 32 0a
Teratoma 28 20 (71%)
Choriocarcinoma 7 7 (100%)
a EGFR expression was observed in syncytiotrophoblastic cells of 5 seminoma, 20 embryonal
carcinoma and 10 yolk sac tumor components
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recently become available [14]. Our result of a rather
restricted EGFR expression pattern suggests that targeting
EGFR signal transduction will be of limited value in the
treatment of patients with TCGT.
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